Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of “Moderate Buy” from Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $21.1250.

A number of research analysts have commented on the company. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Wedbush restated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Citigroup upped their price target on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Finally, Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX opened at $9.47 on Tuesday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The stock’s fifty day moving average is $9.89 and its two-hundred day moving average is $8.73. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $18.49.

Insider Buying and Selling

In other news, CEO Christian Behrenbruch purchased 34,500 shares of the firm’s stock in a transaction on Tuesday, April 28th. The shares were bought at an average cost of $14.48 per share, for a total transaction of $499,560.00. Following the completion of the purchase, the chief executive officer directly owned 20,709,500 shares of the company’s stock, valued at approximately $299,873,560. This trade represents a 0.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TLX. Rhumbline Advisers lifted its stake in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at $89,000. Bank of America Corp DE raised its stake in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares in the last quarter. OLD Mission Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at $111,000. Finally, XY Capital Ltd acquired a new stake in shares of Telix Pharmaceuticals in the first quarter valued at $120,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.